CLINICAL_TRIALS ClinicalTrials.gov record update

Efficacy and Safety Study of DC-CIK Cell Therapy Combined With Epaloliposide, Vortexil, and Regorafenib as Third-line Treatment for Advanced Colorectal Cancer.

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT07343791
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:38.393645+00:00
Published At: 2026-01-15T00:00:00+00:00
Record Updated At: 2026-01-15
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["DC-CIK Treatment", "Regorafenib", "Colorectal Cancer", "Immune Combination Therapy", "Iparomlimab and Tuvonralimab Injection"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-01-15"
protocolSection.identificationModule.nctId: "NCT07343791"
protocolSection.identificationModule.officialTitle: "Efficacy and Safety Study of DC-CIK Cell Therapy Combined With Epaloliposide, Vortexil, and Regorafenib as Third-line Treatment for Advanced Colorectal Cancer."
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["EARLY_PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.